<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01531075</url>
  </required_header>
  <id_info>
    <org_study_id>sor026511ctil</org_study_id>
    <nct_id>NCT01531075</nct_id>
  </id_info>
  <brief_title>Hepatitis B Vaccine in Patients With Inflammatory Bowel Disease</brief_title>
  <acronym>HBV VIP</acronym>
  <official_title>Assessment of Hepatitis B Vaccination Efficacy in Patients With Inflammatory Bowel Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soroka University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soroka University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to assess the efficacy of Hepatitis B Virus vaccination in a population of
      IBD patients treated with immunosuppressive medications.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>protective level of anti HBs antibodies</measure>
    <time_frame>1 month after the last does of vaccine</time_frame>
    <description>Antibody titer &gt;10 IU/ml 30 days following last vaccine dose will be considered protective.
In the work done by Altunoz et al., titer rate below 10 IU was observed in 40% of the patients, while 40% of the patients achieved a rate of above 100 IU. Therefore, we can estimate that the geometric mean of distribution is approx. 50 IU. A sample size of 37 patients in each group achieves a power of 80% to detect a ratio above 1.37 between the two vaccinated groups.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>ENGERIX-B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sci-B-Vac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ENGERIX-B (HBV Vaccine)</intervention_name>
    <description>ENGERIX-B (Hepatitis B Vaccine) 20 mcg, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.</description>
    <arm_group_label>ENGERIX-B</arm_group_label>
    <other_name>ENGERIX-B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sci-B-Vac</intervention_name>
    <description>Sci-B-Vac (Hepatitis B Vaccine) 10 μg/ml, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.</description>
    <arm_group_label>Sci-B-Vac</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male/female ≥ 18 years of age

          -  Evidence of IBD as diagnosed by clinical, laboratory imaging and endoscopic criteria.

          -  Treated with at least one immunosuppressive medication at the time of study initiation

          -  Provided written informed consent.

        Exclusion Criteria:

          -  Pregnant women

          -  Diagnosis of chronic viral hepatitis B

          -  Any major acute medical event in the 30 days prior to recruitment that necessitated
             hospitalization ( acute myocardial infarction, CVA, pulmonary emboli, sepsis, major
             trauma)

          -  Any other chronic inflammatory condition not related to IBD ( connective tissue
             disease, Chronic liver disease, COPD, poorly controlled diabetes mellitus)

          -  Active hematologic or oncologic diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ohad Etzion, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soroka UMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ohad Etzion, MD</last_name>
    <phone>+972-504994721</phone>
    <email>ohadet@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Soroka UMC</name>
      <address>
        <city>Beer- Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayala Dvir, M.Sc</last_name>
      <phone>+972-86244245</phone>
    </contact>
    <investigator>
      <last_name>Olga Abel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2012</study_first_submitted>
  <study_first_submitted_qc>February 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2012</study_first_posted>
  <last_update_submitted>June 6, 2012</last_update_submitted>
  <last_update_submitted_qc>June 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Soroka University Medical Center</investigator_affiliation>
    <investigator_full_name>Ohad Etzion</investigator_full_name>
    <investigator_title>Senior physician, Department of Gastroenterology and Liver Disease</investigator_title>
  </responsible_party>
  <keyword>HBV, Inflammatory bowel disease, immunosuppressor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

